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Abstract  
The down-regulation of the catalytic subunit of the mitochondrial H+-ATP 
synthase (β-F1-ATPase) is a hallmark of most human carcinomas. This characteristic of 
the cancer cell provides a proteomic signature of cellular bioenergetics that can predict 
the prognosis of colon, lung and breast cancer patients. Here we show that the in vivo 
tumor glucose uptake of lung carcinomas, as assessed by positron emission tomography 
in hundred and ten patients using [18F] 2-deoxy-2-fluoro-D-glucose as probe, inversely 
correlates with the bioenergetic signature determined by immunohistochemical analysis 
in tumor surgical specimens. Moreover, we demonstrate that the rate of aerobic 
glycolysis in cancer cells depends on the activity of oxidative phosphorylation and on 
the cellular expression level of the β-F1-ATPase protein of mitochondrial oxidative 
phosphorylation. The results highlight the relevance of the alteration of the bioenergetic 
function of mitochondria for glucose capture and consumption by aerobic glycolysis in 
carcinomas.  
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Introduction 
The cellular uptake of the non-metabolizable [18F] 2-deoxy-2-fluoro-D-glucose 
(FDG) used in positron emission tomography (PET) has emerged as a valuable tool for 
diagnosing and staging cancer patients (1). Tumor capture of FDG is expressed by the 
Standardized Uptake Value (SUV), a measure that provides an indication of the first 
committed step of glucose metabolism and thus, an estimation of glucose consumption 
by tumor cells. The increased glucose capture of tumor cells could result from an 
augmented demand of carbon skeletons to sustain uncontrolled proliferation and/or 
from a shift in the pathway used for energy provision during cellular proliferation. The 
latter was suggested by Otto Warburg many years ago (2), but remained largely 
unexplored until the recent renaissance of the so-called “Warburg effect” in cancer 
biology (3).  
Over the past years, it has been shown that most types of cancers (4,5 and 
references therein) including lung carcinomas (6), fit the Warburg hypothesis since a 
decreased expression of β-F1-ATPase, which is the catalytic subunit of the 
mitochondrial H+-ATP synthase and thus, a bottle-neck of mitochondrial oxidative 
phosphorylation, is linked to an increased expression of several markers of the 
glycolytic pathway in the cancer cell (4,5). This proteomic feature of cancer was 
defined as “the bioenergetic signature” of tumors and shown to provide a relevant 
marker of disease progression in colon, lung and breast cancer patients (4-6). Moreover, 
it has been predicted that the bioenergetic signature further provides a marker of the 
cellular response to chemotherapy (7).  
On the basis of these findings, in this work we studied whether glucose uptake of 
lung carcinomas as assessed in vivo by FDG-PET imaging in the clinical setting 
correlates with proteomic markers of the bioenergetic signature determined in surgical 
specimens. Moreover, we demonstrate that the rate of aerobic glycolysis in cancer cells 
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depends on the activity of oxidative phosphorylation and on the expression level of 
markers of the bioenergetic signature. These results support in part that the increased 
glucose avidity of carcinomas results from a shift in the pathways of energy provision in 
the cancer cell and thus support Warburg’s hypothesis.     
 
 
Materials and Methods 
Study Procedures and Clinical Information of Patients. Surgical specimens, study 
procedures and clinical information of patients with potentially respectable non-small 
cell lung cancer (NSCLC) included in this study were those described previously (8). 
The study was performed between February 1999 and May 2001 at the Hospital 
Universitario 12 de Octubre de Madrid, Spain. A summary of relevant clinico-
pathological information of the cohort of patients analyzed is provided in Table 1.  
Immunohistochemistry. Tissue microarrays containing triplicate 1 mm cores from 
selected tumor areas of formalin-fixed, paraffin-embedded tissue blocks of lung 
carcinomas were constructed using a tissue microarrayer (Beecher Instruments, Silver 
Spring, MD). For immunohistochemical analysis the following primary antibodies were 
used: anti-β-F1-ATPase (1:3,000) (4), anti-Hsp60 (SPA 807, Stressgene, Canada 
1:400), anti-glyceraldehyde-3-phosphate dehydrogenase (GADPH 1:8,000) and anti-
pyruvate kinase (PK 1:2,000) both from Abcam (Cambridge, UK). The expression level 
of the markers was scored as previously described (4) (see also Fig. 1).  
Cell cultures. Human liver (HepG2), lung (HOP62) and colon (KM12 and HCT116) 
cancer cells were grown at 37ºC in culture medium supplemented with 10% FCS. To 
change the bioenergetic phenotype of HCT116 cells (9), cells were incubated with 6 µM 
oligomycin or 10mM 2-desoxiglucose during 2 days. Cells were recovered from the 
plates by trypsin treatment and cellular lysates prepared.  For Western blotting, cellular 
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proteins (10 or 15 µg of protein) were fractionated on 10% SDS-PAGE and membranes 
blotted with anti-β-F1-ATPase (1:20,000), anti-hsp60 (1:2,000), anti-GAPDH 
(1:20,000) and anti-PK (1:1,000). Secondary horseradish peroxidase conjugated goat 
anti-rabbit or anti-mouse or anti-goat antibody (1:3,000 dilution) were used for 
detection, which was accomplished using an enhanced chemiluminescence detection 
method (Amersham Pharmacia Biotech, U.K.). For the determination of aerobic 
glycolysis, cells were seeded and allowed to grow until reaching 60 % confluence. Cells 
were incubated with or without 6 µM oligomycin to assess the relevance of oxidative 
phosphorylation in the rates of aerobic glycolysis. At various times, 0.1 ml aliquots of 
the culture media were collected and precipitated in 6% perchloric acid, neutralized and 
used for the enzymatic determination of lactate as described previously (10). 
Statistical analysis. Pearson’s correlation coefficient, Spearman’s Rho and Kendall’s 
Tau were used as measures of linear correlation among the variables. Simple and 
multiple linear regression models were fitted to the data. Response variables were SUV 
and TSN-SUV. Explanatory variables were the expression level of mitochondrial and 
glycolytic markers. In all the cases the global significance of the models and the 
individual significance of each explanatory variable were assessed using standard F and 
Student’s t tests. One-way analysis of variance was used to detect differences in SUV 
for different levels of β-F1-ATPase/GAPDH ratio in the tumors. Standard F tests were 
used to assess significance. To determine the degree of association of SUV and β-F1-
ATPase expression with survival, cutoff points of both variables were used to define 
potentially “high” and “low” risk groups. For each situation, survival curves were 
computed using Kaplan-Meier estimates and compared using the log-rank test. All the 
computations were carried out using the statistical software package SPSS 13.0. 
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Results  
A set of 110 lung carcinomas with full clinical annotation including PET data 
were studied (Table 1) (8). Tissue sections were reviewed by two pathologists to 
reclassify lung tumors according to the 2004 WHO Classification. Sections were 
processed for immunohistochemical analysis of mitochondrial (β-F1-ATPase and 
Hsp60) and glycolytic (GAPDH and PK) markers of the bioenergetic signature of the 
cell (Fig. 1) (4,5). The maximum FDG uptake of the tumor assessed by SUV was also 
normalized for the tumor size (TSN-SUV), using for this purpose the largest diameter 
(cm) of the surgical specimen.  
We observed that in our cohort of patients a lower SUV of the tumor was a 
significant prognostic factor of survival (Fig. 2a), consistent with recent findings (11). A 
direct linear correlation was observed between tumor SUV data and the expression level 
of GAPDH (R= 0.196, P= 0.044) suggesting that glucose capture by the tumor is linked 
to its rate of utilization by glycolysis. Although no correlation was observed between 
tumor SUV data and PK expression, both glycolytic markers (PK and GAPDH) 
significantly correlated in the surgical specimens (R= 0.368, P<0.001), supporting a 
concerted adaptation of lung tumors to a glycolytic phenotype (4,5). A significant 
inverse correlation was found between TSN-SUV values and the expression level of β-
F1-ATPase in the tumors (R= - 0.308, P= 0.004). In contrast with this finding, no 
correlation was observed between the expression of Hsp60, a structural marker of 
mitochondria, and SUV or TSN-SUV data, suggesting that the loss of the bioenergetic 
marker of mitochondria underlies the increased glucose uptake of the cancer cell. 
Multiple linear regression models for the response variables SUV and TSN-SUV as a 
function of the markers of the bioenergetic signature confirmed the significance of 
GAPDH (P=0.019) and β-F1-ATPase (P=0.005) expression, respectively. In agreement 
with previous findings (6), it was found that patients with a higher tumor expression 
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level of β-F1-ATPase had a higher life expectancy (Fig. 2b), whereas other markers 
provided no meaningful correlations with survival.  
The β-F1-ATPase/GAPDH ratio is a proteomic index of the overall 
mitochondrial capacity of the cell (4-6). Consistent with the above observations it was 
found that squamous cell carcinomas displayed a lower β-F1-ATPase/GAPDH ratio 
than lung adenocarcinomas (Fig. 2c) and had significantly higher SUV values (Fig. 2c). 
Moreover, the stratification of lung carcinomas based on the overall mitochondrial 
capacity of the cell also significantly related (P= 0.048) with the rates of glucose 
consumption as assessed by FDG capture (Fig. 2d).   
To illustrate the relevance of oxidative phosphorylation in the rate of glucose 
consumption by aerobic glycolysis various human cancer cell lines were treated with 
oligomycin, an inhibitor of the mitochondrial H+-ATP synthase. Oligomycin treatment 
promoted a rapid burst in glucose consumption in the cells as assessed by the rapid 
increase in their rates of aerobic glycolysis (Fig. 3a). Likewise, the regulation of the 
overall mitochondrial activity of HCT116 cells (9), that results in cells expressing 
different levels of β-F1-ATPase (Fig. 3b), also showed a significant inverse relationship 
(P< 0.001) between the rates of glucose consumption by aerobic glycolysis and the 
mitochondrial capacity of the cell (Fig. 3b). Taken together, these results highlight both 
in vivo and in vitro the relevance of the bioenergetic function of mitochondria for 
cellular glucose uptake and consumption and support that an altered oxidative 
phosphorylation, by affecting the expression level of β-F1-ATPase, is one of the 
determinants that underlies the abnormal aerobic glycolysis of the cancer cell.  
 
Discussion 
The onset of the Warburg effect in the cancer cell, i.e., the shift to a glycolytic 
phenotype, has been explained on the grounds of (i) metabolic adaptation to the hypoxic 
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environment where the tumor develops (12) and/or by a direct effect of HIF1α on 
mitochondrial bioenergetics (13), (ii) mutations in oncogenes and proteins related to 
signal transduction pathways (myc, Akt, mTOR) that in turn promote changes in the 
expression of genes involved in cellular energetic metabolism (10,14) or directly 
interfere with mitochondrial bioenergetics by affecting the biogenesis of specific 
respiratory complexes (15) and finally, (iii) by mutations on mtDNA (16) or in nuclear 
genes involved in the metabolic and bioenergetic function of the organelle (17). 
However, superimposed to any of these genetic and/or epigenetic alterations, it is 
possible that the shift to a glycolytic phenotype is hard-wired in cancer cells because 
glycolysis is the metabolic pathway required for cellular proliferation. In fact, it has 
been described that lymphocytes shift to glycolysis during cellular proliferation (18). 
Moreover, progression through the cell cycle is supported by non-respiratory modes of 
energy generation as a result of the inhibition of mitochondrial function by cyclin D1 
(19). In this regard, the late cell-cycle biosynthesis of β-F1-ATPase, that mostly occurs 
at G2/M by a mechanism that requires the internal ribosome entry site translational 
activity of the 3’UTR of the transcript (20), could suggest that differences in the 
bioenergetic signature of tumor specimens might also arise as a result of diverse rates of 
cellular proliferation in the tumor.  
Overall, we provide for the first time a link between the expression of a 
mitochondrial protein involved in energy transduction (β-F1-ATPase) and the functional 
estimation of the rate of glucose capture and consumption in cancer cells. These results 
support Warburg’s hypothesis and afford a mechanistic explanation for FDG-PET 
imaging in oncology.  
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Table 1. Summary of clinicopathological characteristics of the cohort of patients studied. 
 
Characteristics No. Percentage 
Age, years 
  
Range          43-82                  -- 
Mean               65                  -- 
Gender 
  
Male 104 96 
Female 6 4 
Histology 
  
SCC 63 57 
AC 26 24 
Others 21 19 
T stage 
  
T1 25 23 
T2 65 59 
T3 12 11 
T4 8 7 
N stage 
  
N0 65 59 
N1 17 15 
N2 23 21 
N3 5 5 
M stage 
  
M0 93 85 
M1 17 15 
SUV 
  
< 5.0 40 36 
> 5.0 68 62 
Unknow 2 2 
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Figure 1. Expression of markers of the bioenergetic signature in lung carcinomas. 
Tissue microarray sections were cut and processed for immunohistochemical analysis of 
the markers of the bioenergetic signature. Representative examples of low (panels to the 
left) and high (panels to the right) expression levels of the mitochondrial β-F1-ATPase 
and Hsp60 as well as of the glycolytic GAPDH and PK markers are shown. Note the 
preferential granular perinuclear staining of the cytoplasm revealing mitochondria in β-
F1-ATPase and Hsp60 and the diffuse staining of the  cytoplasm in GAPDH and PK. 
 
 
Figure 2. Tumor glucose uptake and the bioenergetic signature of NSCLC.  a and 
b, Kaplan-Meier survival analysis shows the association of FDG uptake (SUV) and β-
F1-ATPase expression in lung cancer with overall patients’ survival (OS), respectively. 
c, The bioenergetic signature (β-F1-ATPase/GAPDH ratio) and FDG uptake (SUV) of 
adenocarcinomas (AC) and squamous carcinomas (SCC) of the lung. The results shown 
are the mean ± SEM of 26 and 63 tumors for AC and SCC, respectively. *, P<0.05 and 
**, P<0.01 when compared with AC. d, The bioenergetic signature of lung carcinomas 
defines the rates of glucose uptake (SUV) as assessed by FDG-PET. The results shown 
are the mean ± SEM of 33/32, 38/37 and 37/37 tumors for β-F1-ATPase/GAPDH ratio 
and SUV data, respectively. The relationship between both parameters is significant 
(P=0.048) as assessed by standard F test in a one-way Anova model.  
 
 
Figure 3. The activity of oxidative phosphorylation and the bioenergetic signature 
of the cell define the rate of glucose consumption by aerobic glycolysis. a, The flux 
of aerobic glycolysis of cancer cells (HepG2, HOP62 and KM12) increases when the 
activity of the mitochondrial H+-ATPase is inhibited by incubation of the cells with 
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oligomycin (+). The results shown are the means ± SEM of 3-6 determinations. *, 
P<0.05 and **, P<0.005 when compared with non-treated (-) cells. b, The bioenergetic 
signature (β-F1-ATPase/GAPDH ratio) of HCT116 cells defines the rates of glucose 
utilization by aerobic glycolysis. HCT116 cells were incubated with 10mM 2-
desoxiglucose (hatched symbol), 6 µM oligomycin (open symbol) or left untreated 
(closed symbol) during 48h to promote changes in the cellular bioenergetic phenotype. 
After removal of the drugs, the cells were maintained in culture for the determination of 
the bioenergetic signature and rates of glycolysis. The results shown are the mean ± 
SEM of 4 (hatched), 9 (closed) and 5 (open) independent determinations of the β-F1-
ATPase/GAPDH ratio and 6 (hatched), 15 (closed) and 8 (open) determinations of the 
glycolytic flux. The relationship between both parameters is highly significant 
(P<0.001) as assessed by standard F test in a one-way Anova model.  
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